PER 1.27% 8.0¢ percheron therapeutics limited

Ann: Institutional Placement and proposed Share Purchase Plan SPP, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,697 Posts.
    lightbulb Created with Sketch. 827
    Well over $8 m raised...that's nice..

    Obviously not relying on the SPP....anything there will be a bonus but as per HC discussions , most will take up the SPP.

    This quote pretty much sums up the investment in ANP for the next few months / years...

    Obviously life changing if the drug shows what it's capable of in one ongoing trial...

    The new funds will allow us to continue thedevelopment of our clinical programs, in particular funding the ongoing international Phase IIb Clinical
    Trial program for ATL1102 in Duchenne muscular dystrophy, as well as for ongoing working capital.
    The next 12-18 months are an exciting and busy time with results from the mdx DMD mouse study
    anticipated in July ‘23, the Limb Girdle R2 Dystrophy animal study in August ‘23, the 9-month chronic
    toxicology study around May ’24 and the clinical study primary endpoint readout anticipated July ’24”.


    Glh...imo dyor
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.001(1.27%)
Mkt cap ! $82.94M
Open High Low Value Volume
8.0¢ 8.3¢ 7.9¢ $461.5K 5.711M

Buyers (Bids)

No. Vol. Price($)
6 844186 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 292500 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.